GALECTIN THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

12 Apr 2024 08:45:05 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

11 Apr 2024 14:48:32 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

10 Apr 2024 09:53:14 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

09 Apr 2024 08:50:38 By NetDania Notify

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

08 Apr 2024 15:13:55 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

05 Apr 2024 08:46:14 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

04 Apr 2024 11:26:47 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

03 Apr 2024 11:18:08 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

02 Apr 2024 11:37:00 By NetDania Notify

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

22 Mar 2024 08:45:05 By NetDania Notify

NetDania - New 12 months High: GALECTIN THERAPEUTICS INC. - COMMON STOCK

21 Mar 2024 10:50:02 By NetDania Notify

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 Nov 2023 07:45:52 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 Nov 2023 07:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD

03 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023

23 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors

12 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire